Medicines and chemicals are huge exports for European Union countries. That makes the sector a weak spot as trade tensions ...

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold ...

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...

Recent health news highlights Germany's Merck's acquisition talks with SpringWorks, U.S. Justice Department's disbanding of a ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...